- Investing Ideas
- Australian Pharmaceuticals & Biotech High Insider Buying
Australian Pharmaceuticals & Biotech High Insider Buying
Results
23
Stocks with high levels of insider buying the past 3 months and good analyst coverage.
23 companies
CSL
Market Cap: AU$51.8b
Engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.
CSL
AU$116.32
7D
8.2%
1Y
-51.6%
Telix Pharmaceuticals
Market Cap: AU$4.9b
A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
TLX
AU$14.50
7D
6.6%
1Y
-41.8%
Mesoblast
Market Cap: AU$2.7b
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
MSB
AU$2.13
7D
9.2%
1Y
29.9%
PYC Therapeutics
Market Cap: AU$1.4b
A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.
PYC
AU$1.52
7D
24.6%
1Y
32.2%
Racura Oncology
Market Cap: AU$468.1m
Operates as a Phase 3 clinical biopharmaceutical company for cancer care.
RAC
AU$2.43
7D
1.3%
1Y
82.0%
Starpharma Holdings
Market Cap: AU$294.8m
A biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally.
SPL
AU$0.69
7D
2.2%
1Y
689.8%
Orthocell
Market Cap: AU$209.6m
A regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally.
OCC
AU$0.73
7D
0%
1Y
-38.2%
Actinogen Medical
Market Cap: AU$131.7m
A biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia.
ACW
AU$0.035
7D
2.9%
1Y
84.2%
Nyrada
Market Cap: AU$113.9m
A pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases.
NYR
AU$0.47
7D
5.7%
1Y
89.8%
Arovella Therapeutics
Market Cap: AU$87.0m
A biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally.
ALA
AU$0.071
7D
6.0%
1Y
-26.0%
Radiopharm Theranostics
Market Cap: AU$70.9m
A clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.
RAD
AU$0.02
7D
0%
1Y
-16.7%
Botanix Pharmaceuticals
Market Cap: AU$60.2m
Operates as a commercial dermatology company in Australia and the United States.
BOT
AU$0.022
7D
-4.3%
1Y
-92.7%
Entropy Neurodynamics
Market Cap: AU$52.2m
A clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States.
ENP
AU$0.03
7D
-3.2%
1Y
-3.2%
Nexsen
Market Cap: AU$44.0m
Operates as a nanobiotechnology company that develops proprietary biosensing platforms for rapid, high-precision point-of-care (POC) medical diagnostics and point-of-use sensing for veterinary, agricultural, and biosecurity applications.
NXN
AU$0.23
7D
-10.0%
1Y
n/a
Imugene
Market Cap: AU$39.5m
A clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.
IMU
AU$0.12
7D
26.4%
1Y
-75.8%
Trajan Group Holdings
Market Cap: AU$38.1m
Develops, manufactures, and sells analytical and life science products and devices in Malaysia, Japan, Australia, New Zealand, the United States, Europe, the Middle East, Africa, and India.
TRJ
AU$0.27
7D
-18.5%
1Y
-63.9%
Peak Processing
Market Cap: AU$17.4m
Manufactures, distributes, and sells recreational cannabis products in Canada and the United States.
PKP
AU$0.017
7D
13.3%
1Y
-37.0%
IDT Australia
Market Cap: AU$14.1m
Engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the United States.
IDT
AU$0.034
7D
0%
1Y
-63.0%
Firebrick Pharma
Market Cap: AU$11.4m
Engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally.
FRE
AU$0.037
7D
-5.1%
1Y
-47.1%
Vectus Biosystems
Market Cap: AU$9.2m
Engages in the medical research and development activities in Australia.
VBS
AU$0.15
7D
11.1%
1Y
248.8%
Epsilon Healthcare
Market Cap: AU$8.8m
Engages in the healthcare business in Australia.
EPN
AU$0.022
7D
-4.3%
1Y
n/a
Percheron Therapeutics
Market Cap: AU$6.9m
Engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia.
PER
AU$0.005
7D
25.0%
1Y
-50.0%
Chimeric Therapeutics
Market Cap: AU$3.7m
A clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia.
CHM
AU$0.065
7D
-13.3%
1Y
-83.8%